SOMERVILLE, NJ / ACCESSWIRE / October 6, 2024 / Asentech LLC proudly announces its Gold win at the prestigious 2024 PM360 Trailblazer Awards in the App/Digital Solution category. This recognition solidifies Asentech’s position as a leader in digital healthcare solutions, reflecting its unwavering commitment to driving transformative innovations within the life sciences industry.
The PM360 Trailblazer Awards honor the most impactful achievements in healthcare marketing, recognizing companies that excel in creativity, strategy, and social responsibility. Asentech’s Gold Award for App/Digital Solution stands as a testament to the company’s success in delivering breakthrough digital solutions designed to meet the evolving needs of healthcare providers and patients alike.
“We are thrilled to be recognized for our dedication to elevating healthcare through technology,” said Anil Bhaskar, Managing Partner at Asentech LLC. “Our success is a testament to the exceptional partnerships we’ve forged with our clients. Through collaborative efforts, we create innovative solutions that empower healthcare challenger brands to reach their full potential.”
Asentech’s cutting-edge digital solutions are designed to simplify complex healthcare challenges, enhancing engagement, compliance, and operational efficiencies. With a deep understanding of healthcare regulations and a forward-thinking approach, Asentech delivers solutions that make a tangible impact across the healthcare ecosystem.
Visit asentechllc.com to learn more about us.
About Asentech
Asentech leads in digital transformation for Life Sciences brands, offering advanced data and technology solutions to amplify customer engagement across multiple channels through data-driven strategies and omnichannel approaches.
Contact:
Rashmi Khairnar
rashmi.khairnar@asentech.com
https://www.asentechllc.com/
SOURCE: Asentech
View the original press release on accesswire.com
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…
The AI-enabled clinical assistant is available to query patient data across the EHR as well…
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…
First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
